«Biotech players OWL and BIOSFER have entered into a strategic partnership with a view to strengthening R&D in developing diagnosis methods and personalised medicine using metabolomics. «

«The contract allows both parties to identify opportunities, generate specific proposals and find the most appropriate funding to ensure the success of these projects and make them beneficial both for society and for the biotechnology industry. 

Both OWL and BIOSFER have extensive experience in metabolomic technology for application in a range of areas: developing new biomarkers for the creation of diagnostic products or promoting innovative platforms for studies and clinical trials in the pharmaceutical industry.»

Article written by Med-Tech Innovation



Med-Tech Innovation – News